Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.

Amuge, Pauline; Lugemwa, Abbas; Wynne, Ben; Mujuru, Hilda A; Violari, Avy; Kityo, Cissy M; Archary, Moherndran; Variava, Ebrahim; White, Ellen; Turner, Rebecca M; +20 more... Shakeshaft, Clare; Ali, Shabinah; Nathoo, Kusum J; Atwine, Lorna; Liberty, Afaaf; Bbuye, Dickson; Kaudha, Elizabeth; Mngqibisa, Rosie; Mosala, Modehei; Mumbiro, Vivian; Nanduudu, Annet; Ankunda, Rogers; Maseko, Lindiwe; Kekitiinwa, Adeodata R; Giaquinto, Carlo; Rojo, Pablo; Gibb, Diana M; Turkova, Anna; Ford, Deborah; ODYSSEY Trial Team; (2022) Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. The Lancet HIV, 9 (9). e638-e648. ISSN 2405-4704 DOI: https://doi.org/10.1016/S2352-3018(22)00163-1

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S2352-3018(22)00163-1

Abstract

Share

Download

Filename: Amuge_etal_2022_Once-daily-dolutegravir-based-antiretroviral.pdf

Licence: Creative Commons: Attribution 4.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar